001367.SZ
海森药业
SZSE · C 制造业 · CN
CNY 20.44
−6.24%Year over year
Reported trailing growth
- Revenue
- +9.9%
- EBITDA
- —
- EBIT
- +11.1%
- EPS
- +10.6%
- Free cash flow
- -45.0%
- Operating cash flow
- -12.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +8.0%
- EBITDA
- +9.4%
- EBIT
- +8.8%
- Net income
- +8.1%
- EPS
- -24.4%
- Free cash flow
- -22.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026